Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Malignant Intracranial High Grade Glioma and Current Treatment Strategy

Malignant high-grade glioma (HGG) is the most common and extremely fatal type of primary intracranial tumor. These tumors recurred within 2 to 3 cm of the primary region of tumor resection in the majority of cases. Furthermore, the blood-brain barrier significantly limited the access of many systemically administered chemotherapeutics to the tumor, pointing towards a stringent need for new therapeutic patterns. Therefore, targeting therapy using local drug delivery for HGG becomes a priority for the development of novel therapeutic strategies. The main objectives to the effective use of chemotherapy for HGG include the drug delivery to the tumor region and the infusion of chemotherapeutic agents into the vascular supply of a tumor directly, which could improve the pharmacokinetic profile by enhancing drug delivery to the neoplasm tissue. Herein, we reviewed clinical and molecular features, different methods of chemotherapy application in HGGs, especially the existing and promising targeting therapies using local drug delivery for HGG which could effectively inhibit tumor invasion, proliferation and recurrence of HGG to combat the deadly disease. Undoubtedly, novel chemical medicines targeting these HGG may represent one of the most important directions in the Neuro-oncology

Year of Publication: 2019
Contained in: Current cancer drug targets Vol. 19, No. 2 (2019), p. 101-108
All journal articles: Search for all articles in this journal
Language: English
Contributors: Zhang, Xiang | Author
Zhang, Wei
Mao, Xing-Gang
Cao, Wei-Dong
Zhen, Hai-Ning
Hu, Shi-Jie
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Genetic alterations
Glioma
Journal Article
Research Support, Non-U.S. Gov't
blood-brain barrier
chemotherapy
drug delivery
malignant high-grade glioma.
ISSN: 1873-5576
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 27.01.2020
published: Print
Citation Status In-Process
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.2174/1568009618666180530090922
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03258nma a2200589 c 4500
001 NLM285269259
003 DE-601
005 20200220225705.0
007 cr uuu---uuuuu
008 180604s2019 000 0 eng d
024 7 |a 10.2174/1568009618666180530090922  |2 doi 
028 5 2 |a pubmed20n1065.xml 
035 |a (DE-599)NLM29848277 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Zhang, Xiang 
245 1 0 |a Malignant Intracranial High Grade Glioma and Current Treatment Strategy  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Revised 27.01.2020 
500 |a published: Print 
500 |a Citation Status In-Process 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. 
520 |a Malignant high-grade glioma (HGG) is the most common and extremely fatal type of primary intracranial tumor. These tumors recurred within 2 to 3 cm of the primary region of tumor resection in the majority of cases. Furthermore, the blood-brain barrier significantly limited the access of many systemically administered chemotherapeutics to the tumor, pointing towards a stringent need for new therapeutic patterns. Therefore, targeting therapy using local drug delivery for HGG becomes a priority for the development of novel therapeutic strategies. The main objectives to the effective use of chemotherapy for HGG include the drug delivery to the tumor region and the infusion of chemotherapeutic agents into the vascular supply of a tumor directly, which could improve the pharmacokinetic profile by enhancing drug delivery to the neoplasm tissue. Herein, we reviewed clinical and molecular features, different methods of chemotherapy application in HGGs, especially the existing and promising targeting therapies using local drug delivery for HGG which could effectively inhibit tumor invasion, proliferation and recurrence of HGG to combat the deadly disease. Undoubtedly, novel chemical medicines targeting these HGG may represent one of the most important directions in the Neuro-oncology 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Research Support, Non-U.S. Gov't  |2 gnd 
655 7 |a Genetic alterations  |2 gnd 
655 7 |a Glioma  |2 gnd 
655 7 |a blood-brain barrier  |2 gnd 
655 7 |a chemotherapy  |2 gnd 
655 7 |a drug delivery  |2 gnd 
655 7 |a malignant high-grade glioma.  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Research Support, Non-U.S. Gov't 
689 0 |5 DE-601 
689 1 0 |a Genetic alterations 
689 1 1 |a Glioma 
689 1 2 |a blood-brain barrier 
689 1 3 |a chemotherapy 
689 1 4 |a drug delivery 
689 1 5 |a malignant high-grade glioma. 
689 1 |5 DE-601 
700 1 |a Zhang, Wei 
700 1 |a Mao, Xing-Gang 
700 1 |a Cao, Wei-Dong 
700 1 |a Zhen, Hai-Ning 
700 1 |a Hu, Shi-Jie 
773 0 8 |i in  |t Current cancer drug targets  |g Vol. 19, No. 2 (2019), p. 101-108  |q 19:2<101-108  |w (DE-601)NLM120493810  |x 1873-5576 
856 4 1 |u http://dx.doi.org/10.2174/1568009618666180530090922  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 19  |j 2019  |e 2  |h 101-108